Pfizer has announced today that new test results show its coronavirus vaccine is 95% effective, and protects older people most at risk of dying.
Pfizer Inc. and BioNTech says after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints.
Analysis of the data indicates a vaccine efficacy rate of 95%, while the observed efficacy in adults over 65 years of age was over 94%.
Last week, the early results had suggested 90% efficacy.
Pfizer says the only side effects reported so far are fatigue (2%) and headache (3.8%).
Pfizer and BioNTech plan to submit a request within days to the FDA for an EUA based on the totality of safety and efficacy data collected to date, as well as manufacturing data relating to the quality and consistency of the vaccine.
Pfizer is confident in its vast experience, expertise and existing cold-chain infrastructure to distribute the vaccine around the world.
For more details on the official announcement, please click here.
Most Canadians could be vaccinated against COVID-19 by the end of next year.
That’s according to Canada’s deputy chief public health officer.
Dr. Howard Njoo said yesterday that he is optimistic the new vaccines can be approved by Health Canada and rolled out soon.
According to a survey by Leger, Sixty-nine per cent of respondents said they plan to get inoculated against the novel coronavirus once Health Canada approves a vaccine that is broadly available and free.
https://www.facebook.com/Pfizer/photos/a.390855402242/10158733998432243/?type=3&size=1411%2C792&fbid=10158733998432243&source=12&player_origin=pages&__xts__[0]=68.ARBKfC6jTy712BMCOkteOhW4CKgCou4ZteK8zGWl9ld7zFeOGN61JDgRPSrfkGto4sUBkRspPMhuFqUiO2LEBGox2hx9Pvey6CsJUD7mRHKldA06rXox0__uWz4JH9N-Ahs8OKJ9K9mNssO-iFuResDpMx19L3O8vgifmnwzdvZIUB4R2S4sdqtYAJQdbSW-JaViPpMWvsM1SPLP4NfcjYU9qLmXRxBfls4aS3X0a5MJpXfFQhzMFkZU-7Tdrnun82ubvSeR9uAMl_tTBQQOUKgSUG7j6rnfDUVxJXFlzsWjrWQe95kpNOlrXEDadwWjr9awc3ohcUsMjxnSkTd0